879399-82-3

Upstream product

• 879402-30-9 (2S)-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}chloroacetamide 
• 38449-49-9 2-mercapto-thiazole-4-acetic acid,ethyl ester 
• 879402-33-2 (2S)-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-[4-(ethoxycarbonylmethyl)thiazol-2-ylthio]acetamide 
• 407640-11-3 (2S)-2-aminomethyl-4-(3,4-dichlorobenzyl)morpholine 
• 610305-43-6 2-{[(2R)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-1H-isoindole-1,3-(2H)-dione 

Downstream Products

• 1002092-13-8 (2S)-[4-(carboxymethyl)thiazol-2-ylthio]-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide potassium salt 
• 1002092-12-7 (2S)-[4-(carboxymethyl)thiazol-2-ylthio]-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide hydrobromide 

Relevant academic research and scientific papers

THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE

The present invention provides a therapeutic agent or prophylactic agent for an ophthalmic disease caused by ocular angiogenesis, which contains a morpholine compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) a

SALT OF MORPHOLINE COMPOUND

(2S)-[4-(Carboxymethyl)thiazol-2-ylthio]-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide hydrobromide and a crystal thereof, which resist easy weight change caused by vapor sorption as compared to a free form, and are superior as drug substances

MORPHOLINE COMPOUND

A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.